Jounce Therapeutics
A clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients.
Launch date
Employees
Market cap
€89.0m
Enterprise valuation
(€74m) (Public information from May 2023)
Share price
$1.88 JNCE
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 71.6m | 65.2m | 148m | 62.3m | 26.9m | 82.0m |
| % growth | - | (9 %) | 127 % | (58 %) | (57 %) | 205 % |
| EBITDA | (14.8m) | (27.5m) | 56.7m | (41.7m) | (88.2m) | (50.2m) |
| % EBITDA margin | (21 %) | (42 %) | 38 % | (67 %) | (328 %) | (61 %) |
| Profit | (16.4m) | (27.4m) | 56.8m | (43.8m) | (90.9m) | (50.9m) |
| % profit margin | (23 %) | (42 %) | 38 % | (70 %) | (338 %) | (62 %) |
| EV / revenue | 5.7x | 1.7x | 2.0x | 4.5x | 13.9x | 4.5x |
| EV / EBITDA | -27.8x | -4.0x | 5.1x | -6.7x | -4.2x | -7.4x |
| R&D budget | 67.8m | 70.1m | 67.1m | 78.7m | 89.0m | 103m |
| R&D % of revenue | 95 % | 107 % | 45 % | 126 % | 331 % | 126 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$56.0m | Series B | ||
| N/A | N/A | IPO | |
| N/A | $35.0m | Post IPO Equity | |
| N/A | $56.3m | Post IPO Equity | |
* | N/A | Merger | |
| Total Funding | €93.6m | ||
Related Content
Recent News about Jounce Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Jounce Therapeutics
Edit
ACQUISITION by Jazz Pharmaceuticals Jul 2019